The Rheumatology Network osteoarthritis clinical focus page provides information on the latest osteoarthritis and osteoporosis news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for osteoarthritis drugs.
December 13, 2022
Improvements in GUSS, a validated tool developed to identify changes in hand osteoarthritis over time, were higher in the denosumab group when compared with placebo and the development of new erosive joints was significantly lower at week 48.
October 25, 2022
“The lack of a biomarker of osteoarthritis has hindered development of effective therapies for this common disease,” investigators explained.
October 20, 2022
E Michael Lewiecki, MD, discusses his CCR West presentation “Sequential Therapy in Osteoporosis: When Does the Order Matter?”
October 20, 2022
E Michael Lewiecki, MD, discusses his CCR West presentation “When is Osteopenia Osteoporosis?”
September 26, 2022
Kim Bennell, PhD, discusses her study “Effectiveness of an Unsupervised Online Yoga Program on Pain and Function in People With Knee Osteoarthritis: A Randomized Clinical Trial.”
September 22, 2022
Although results were associative rather than causative, a decrease in BMI may prevent, delay, or slow the structural defects in knee osteoarthritis.
September 21, 2022
"Online interventions have the potential to reach a wide audience, allowing exercise to be undertaken from the comfort and convenience of home and thereby overcoming some of the barriers to exercise reported in the osteoarthritis population.”
March 03, 2022
Aspartyl-alanyl-diketopiperazine (Ampion), an intra-articular injection, works to regulate immune responses that are connected to pain, inflammation, and joint damage in patients with osteoarthritis of the knee.
February 10, 2022
According to the study, weight loss may be an effective strategy to prevent or treat pain in patients with hand osteoarthritis.
January 13, 2022
While investigators were hopeful that duloxetine, an SNRI, would reduce chronic pain in patients with knee osteoarthritis, results were lackluster and clinically insignificant.